Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05371964 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT05371964 · ClinicalTrials.gov record · last posted 2026-08-26

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis

StatusActive, Not Recruiting
PhasePhase 1
Started2022-05-04
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
The purpose of the study is to identify the recommended Part 2 dose (R2PD) of imetelstat sodium in combination with ruxolitinib in participants with myelofibrosis (MF) in Part 1, and to evaluate the safety and preliminary clinical activity of the R2PD of imetelstat sodium in combination with ruxolitinib in participants with MF in Part 2.

Protocol amendment history 2 changes detected by DataLookout

2026-08-27
Enrollment closed, study ongoing
2026-08-27
Enrollment reduced: 36 → 30 participants
Trial Details
NCT Number NCT05371964
Lead Sponsor Geron Corporation
Conditions Myelofibrosis
Enrollment 30 participants
Start Date 2022-05-04
Primary Completion 2027-02 (estimated)
Study Completion 2028-08 (estimated)
Updated on ClinicalTrials.gov 2026-08-26